<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two cases of resistance to the <z:chebi fb="5" ids="28304">heparin</z:chebi> treatment, induced by large consumption of antithrombin III, are reported </plain></SENT>
<SENT sid="1" pm="."><plain>Normally small, this consumption does not automatically call for the systematic dosage of Antithrombin III for each treatment using <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>On the other hand, any clinical or biological resistance to higher doses of <z:chebi fb="5" ids="28304">heparin</z:chebi>, any personal or family history of <z:mp ids='MP_0005048'>thrombosis</z:mp> necessitate the administration of Antithrombin III </plain></SENT>
<SENT sid="3" pm="."><plain>Where there is an acquired or congenital deficit, an injection of Antithrombin III corrects the disorder and reduces the risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In the case of a <z:chebi fb="5" ids="28304">heparin</z:chebi>-antivitamin K relay, it is essential to achieve complete biological effectiveness of the antivitamins K to interrupt the administration of the <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
</text></document>